ZFIN ID: ZDB-FISH-150901-16797
Fish name: mtorxu015Gt/xu015Gt
Genotype: mtorxu015Gt/xu015Gt
Targeting Reagent: none
HUMAN DISEASE MODELED by mtorxu015Gt/xu015Gt
No data available
GENE EXPRESSION
Gene expression in mtorxu015Gt/xu015Gt
Reporter gene expression No data available
PHENOTYPE
Phenotype in mtorxu015Gt/xu015Gt
Phenotype Conditions Figures
brain has normal numbers of parts of type microglial cell, normal standard conditions Fig. 6 with image from Shen et al., 2016
cardiac muscle cell decreased size, abnormal standard conditions Fig. 3 from Ding et al., 2011
cell proliferation involved in heart morphogenesis decreased occurrence, abnormal standard conditions Fig. 3 from Ding et al., 2011
liver decreased size, abnormal control Fig. 4 from Chaturantabut et al., 2019
liver decreased size, abnormal chemical treatment by environment: G-1 Fig. 4 from Chaturantabut et al., 2019
liver decreased size, abnormal chemical treatment by environment: 17beta-estradiol Fig. 4 from Chaturantabut et al., 2019
liver low brightness, abnormal standard conditions Fig. 3 from Ding et al., 2011
spinal cord has fewer parts of type oligodendrocyte, abnormal standard conditions Fig. 2Fig. 3 from Kearns et al., 2015
spinal cord central nervous system myelination decreased occurrence, abnormal standard conditions Fig. 2 from Kearns et al., 2015
spinal cord myelin sheath decreased thickness, abnormal standard conditions Fig. 2 from Kearns et al., 2015
spinal cord oligodendrocyte plp1a expression decreased amount, abnormal standard conditions Fig. 2Fig. 3 from Kearns et al., 2015
spinal cord oligodendrocyte ab1-mbp labeling decreased amount, abnormal standard conditions Fig. 2Fig. 3 from Kearns et al., 2015
spinal cord oligodendrocyte cldnk expression decreased amount, abnormal standard conditions Fig. 2Fig. 3 from Kearns et al., 2015
spinal cord oligodendrocyte mbpa expression decreased amount, abnormal standard conditions Fig. 2Fig. 3 from Kearns et al., 2015
trunk curved ventral, abnormal standard conditions Fig. 6 with image from Shen et al., 2016
whole organism ab1-rps6 labeling amount, ameliorated chemical treatment by environment: 17beta-estradiol Fig. 4 from Chaturantabut et al., 2019
whole organism ab1-rps6 labeling amount, ameliorated chemical treatment by environment: G-1 Fig. 4 from Chaturantabut et al., 2019
whole organism mbpa expression decreased amount, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism fdps expression decreased amount, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism dhrs12 expression decreased amount, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism ab1-rps6 labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 4 from Kearns et al., 2015
whole organism hmgcs1 expression decreased amount, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism mpz expression decreased amount, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism hmgcra expression decreased amount, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism ab1-rps6 labeling decreased amount, abnormal standard conditions Fig. 4 from Kearns et al., 2015
whole organism decreased behavioural activity, abnormal standard conditions Fig. 3 from Ding et al., 2011
whole organism decreased size, abnormal standard conditions Fig. 3 from Ding et al., 2011
whole organism viability, abnormal standard conditions text only from Ding et al., 2011
whole organism cholesterol biosynthetic process decreased occurrence, abnormal standard conditions Fig. 2 from Kearns et al., 2015
whole organism TOR signaling decreased occurrence, abnormal chemical treatment: sirolimus Fig. 4 from Kearns et al., 2015
whole organism TOR signaling decreased occurrence, abnormal standard conditions Fig. 4 from Kearns et al., 2015

CITATIONS  (7)